This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Instil Bio, Inc. (TIL) Is Up 4.07% in One Week: What You Should Know
by Zacks Equity Research
Does Instil Bio, Inc. (TIL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Instil Bio (TIL) points to a 246.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Are You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great Choice
by Zacks Equity Research
Does Instil Bio, Inc. (TIL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Summit Therapeutics Stock Nosedives on Mixed NSCLC Study Results
by Zacks Equity Research
SMMT plunges 31% as its NSCLC drug shows strong PFS but misses statistical significance on survival data.
Instil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Instil Bio (TIL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Believe Instil Bio (TIL) Could Rally 343.63%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 343.6% upside potential for Instil Bio (TIL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Here's Why Summit Therapeutics Stock Soared 15% on Friday
by Zacks Equity Research
The surge in SMMT's share price comes after some established investment firms maintain their positive outlook on the company, citing optimism around its lead pipeline drug.
Here's Why Summit Therapeutics Stock Price Rose 6% on Friday
by Zacks Equity Research
SMMT stock rose after analysts at Jefferies initiated coverage on it, citing optimism about the company's lead pipeline drug.
Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy
by Zacks Equity Research
MRK in-licenses a bispecific antibody, based on the same mechanism as SMMT's lead drug, which outperformed its blockbuster drug, Keytruda, in a lung cancer study.
BNTX to Boost Oncology Pipeline With Biotheus Acquisition, Stock Up
by Zacks Equity Research
BioNTech inks a deal to acquire Biotheus and gain full global rights to a bispecific antibody, BNT327/PM8002, being studied for various oncology indications.
Summit Therapeutics Stock: Sell or Hold Before Q3 Earnings?
by Zacks Equity Research
Devoid of any marketed drug in its portfolio, investors will likely focus on SMMT's pipeline updates when it reports third-quarter results this month.
Summit Stock Skyrockets Nearly 700% YTD: Time to Sell or Hold?
by Zacks Equity Research
The rally in SMMT stock is driven by encouraging updates on its oncology candidate, which has the potential to become the next standard of care in the NSCLC space.
Instil Bio Stock Skyrockets 641% in One Week: Here's Why
by Zacks Equity Research
A rival posted encouraging data on a drug that outperformed Keytruda in certain NSCLC patients. TIL licenses a drug candidate that uses a similar mechanism.
What Makes Instil Bio (TIL) a New Buy Stock
by Zacks Equity Research
Instil Bio (TIL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Instil (TIL) Stock Rises More Than 20% in a Week: Here's Why
by Zacks Equity Research
Instil's (TIL) recent deal with a collaborator to carry out preclinical manufacturing feasibility studies on its ITIL-306 program is a positive.
After Plunging -18.52% in 4 Weeks, Here's Why the Trend Might Reverse for Instil Bio, Inc. (TIL)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Instil Bio, Inc. (TIL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Down 61.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Instil Bio, Inc. (TIL)
by Zacks Equity Research
Instil Bio, Inc. (TIL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Down 59.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Instil Bio, Inc. (TIL)
by Zacks Equity Research
Instil Bio, Inc. (TIL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Company News for Mar 8, 2022
by Zacks Equity Research
Companies in The News Are: VET,AMR,TIL,BBBY,GME